We believe this site might serve you best::

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Home » Resources »

Promega Webinars

NA_webinarsConcept-image
Welcome to the Promega Webinar Series, an ongoing communication designed to keep you informed. Learn about basic concepts, tips and techniques to help your research, or understand how products were designed and how to implement in your lab. Most presentations are given by Promega scientists and you will have an opportunity to interact with our Technical Service Scientist directly during live events via chat. The webinars are free though we do ask that you register for the events. Registration allows us to send you the URL for the webinar.

How to Avoid Artificial Non-Enzymatic PTMs During the Peptide Sample Preparation Process

Proteomics

Tuesday, June 13, 2017

Sergei Saveliev, PhD

Non-enzymatic post-translational modifications (PTMs) spontaneously occur in biotherapeutic proteins during manufacturing and storage. These modifications negatively affect efficacy and stability of biotherapeutic proteins. Major non-enzymatic PTMs are deamidation, disulfide bond scrambling and oxidation. These non-enzymatic PTMs are also introduced during protein preparation for peptide mapping and compromise the analysis. Join us as we will discuss sources of these artificial protein modifications as well as procedural optimizations to suppress these PTMs.

Did you miss one of our webinars? Simply select the appropriate link below and view the recorded webinar. It will not be interactive, but you will see the chat questions the original attendees asked. For additional information on the products discussed in the webinar, explore our links to videos and other resources.

If there is an area you would like to see covered, you can request a topic of your choice.

If you are experiencing issues opening the webinar recordings, please be sure that you have the latest Adobe Flash Player installed.

Post-Translational Modification Enzymes: How to Interrogate Key Drug Targets

Cell-Based Assays

Tuesday, April 11, 2017

Hicham Zegzouti, PhD

Post-translational modifications (PTMs), the addition of functional groups to proteins, play a significant role in regulating cellular biology. Examples include phosphorylation, a common mechanism in regulating enzymatic activity, and the addition of carbohydrates to many eukaryotic proteins, which promotes proper folding, improves stability and serves in regulatory functions. A key objective of research and drug discovery surrounding PTMs is to study the regulation of these enzymes and find specific modulators of their activity. Although mass spectrometry, eastern and western blotting detection technologies have been used traditionally, none are amenable to high throughput or as sensitive as bioluminescent detection of nucleotide-based substrates for such enzymes.

Optimizing and Qualifying Reporter Gene Bioassays for Immune Checkpoint Receptors

Drug Discovery

Tuesday, March 28, 2017

Zhijie Jey Cheng, PhD

Reporter gene assays for functional screening and development of antibody drug candidates are gaining popularity due to the significant advantages they offer over traditional methods that rely on human primary immune cells. We will discuss development of a series of MoA-based reporter gene bioassays for antibodies targeting co-inhibitory receptors, co-stimulatory receptors and combination bioassays that target immune checkpoint receptors.

Factors to Consider for Designing and Optimizing Assays Applied to 3D Cultures

Cell-Based Assays

Tuesday, March 14, 2017

Terry Riss, PhD

3D cell culture models present a challenge for using assay chemistries and imaging methods that were originally designed for measuring events from 2D monolayers of cells. In this webinar, we will present factors to consider when designing and optimizing assays applied to 3D cell culture models, case studies describing design of reagents to overcome the limitations inherent with detecting markers from large 3D culture models, and applications of novel real-time detection methods.

MicroRNA Analysis Paired with Novel Cell Health Assays: A Complete Workflow

Genomics

Tuesday, February 28, 2017

Brad Hook, PhD

MicroRNAs (miRNAs) are small-noncoding RNA molecules that regulate gene expression post-transcriptionally. Amplification and overexpression of individual oncomiRs (miRNAs associated with cancer) or genetic loss of tumor suppressor miRNAs are associated with human cancer and are sufficient to drive tumorigenesis in mouse models. A global decrease in miRNA levels has been observed in human cancers and linked to genetic and epigenetic alterations in components of the miRNA biogenesis machinery. Learn more about how to analyze miRNAs in human cancer cells as we present data on a two studies that use new novel assays to monitor cell health and purify total RNA (including miRNAs) from the same cells.

To NanoDrop® or Not to NanoDrop®: Choosing the Most Appropriate Method for Nucleic Acid Quantitation

Genomics

Tuesday, February 14, 2017

Doug Wieczorek, PhD

Success or failure in DNA/RNA analysis applications often comes down to whether or not the appropriate amount of input nucleic acid is used, but nucleic acid quantitation methods reveal different information about a sample. This webinar will review absorbance, fluorescent nucleic acid-binding dyes and qPCR quantitation methods and present the advantages and disadvantages of each method. With this information, you'll be able to choose the appropriate quantitation method based on your sample type and downstream application.

  • Results per page 
  • « 1 2 3 4 5  ... » 
Choose your country

Americas

Brazil
Brazil
Canada
Canada
United States
United States

Pacific Asia

Australia
Australia
India
India
Japan
Japan
Korea, Republic of
Korea, Republic of
Singapore
Singapore

Europe

Austria
Austria
Belgium
Belgium
Denmark
Denmark
Estonia
Estonia
Finland
Finland
France
France
Germany
Germany
Iceland
Iceland
Italy
Italy
Luxembourg
Luxembourg
Netherlands
Netherlands
Norway
Norway
Poland
Poland
Spain
Spain
Sweden
Sweden
Switzerland
Switzerland
United Kingdom
United Kingdom